BCAL Diagnostics moves to reshape Genetic Signatures board
BCAL Diagnostics (ASX: BDX) has issued a notice under section 249D of the Corporations Act 2001 (Cth) to Genetic Signatures (ASX: GSS), requesting that GSS convene a general meeting to consider resolutions to change the board.
As the holder of more than 5% of GSS shares, BCAL is now a substantial holder with 41,923,644 shares, representing 18.46% of the company. The move sees an activist substantial holder seeking to reshape the board of an ASX-listed peer, a material governance event for both share registers.
When big ASX news breaks, our subscribers know first
What the s249D notice is seeking
The notice requests that GSS put three specific resolutions to shareholders at a general meeting:
-
Remove Mr Michael Aicher from office as a director
-
Appoint Ms Susan Forrester to the board
-
Appoint Mr John Melki, a former CEO and director of GSS, to the board
These resolutions were confirmed by GSS in its own announcement to the ASX on the same day, 3 September 2026. The requested changes signal that BCAL is seeking board representation aligned with its shareholding.
How BCAL built its stake
BCAL previously held 23,173,644 shares, equal to 10.2% of GSS. It then acquired a second parcel (the “Second Parcel”) of 18,750,000 shares in an off-market transaction, lifting its total holding to 41,923,644 shares (18.46%).
BCAL built its position in GSS progressively, with the initial 10.2% stake in Genetic Signatures acquired in July 2026 for $1.39 million at 6.0 cents per share, framing the investment at that point as a strategic addition of an infectious disease diagnostics pillar alongside its oncology portfolio.
This increase was disclosed in a substantial holder notice filed with the ASX on 26 August 2026. As stated in that notice, the vendor “remained the registered holder of the Second Parcel, as is always the case, pending registration of the transfer” by the GSS share registry. The transfer of the Second Parcel was registered on 2 September 2026.
According to BCAL, GSS “appears to have reviewed an outdated version of its share register from 31 August 2026.”
| Item | Shares | % Holding | Date/Status |
|---|---|---|---|
| Initial holding | 23,173,644 | 10.2% | Prior holding |
| Second Parcel acquired | 18,750,000 | — | Off-market transaction |
| Total holding | 41,923,644 | 18.46% | Disclosed 26 August 2026 |
| Second Parcel transfer | 18,750,000 | — | Registered 2 September 2026 |
The role of Kidder Williams
BCAL engaged corporate adviser and investment bank Kidder Williams to assist it with the acquisition of its interest in GSS. BCAL understands that Kidder Williams used “an associated entity to facilitate the acquisition in the proper performance of the functions attaching to its professional capacity” in performing that mandate.
BCAL has stated that Kidder Williams is not an associate of BCAL.
Understanding a section 249D notice
A section 249D notice is a mechanism under the Corporations Act 2001 (Cth) that allows shareholders holding at least 5% of the voting shares in a company to require that company to convene a general meeting. It is a recognised tool for shareholders to put board-composition resolutions to a vote of the wider register.
Key mechanics include:
-
Shareholders must hold at least 5% of the voting shares
-
The company is required to convene a general meeting
-
Shareholders then vote on the requested resolutions
The mechanism sets the process in motion, but the outcome of any vote is determined by shareholders at the meeting.
What this means for investors
For GSS shareholders, a governance contest is now underway, with a proposed board reshuffle to be put to a general meeting for consideration. For BCAL shareholders, the company now holds an 18.46% strategic stake in an ASX-listed peer.
BCAL’s broader FY2027 strategy, presented at Bioshares 2026 in August, positioned the Genetic Signatures stake as one component of a multi-pillar investment case that also includes three commercially available blood-based cancer tests and an MSAC reimbursement pathway.
The next procedural step is for GSS to convene a general meeting to consider the resolutions set out in the notice. No meeting date has been disclosed in the announcement.
Authorisation
The announcement was authorised by the Board for release to the ASX. Listed contacts were Jayne Shaw, Non-Executive Chair, and Anne-Louise Arnett, Chief Executive Officer.
Don’t Miss the Next Healthcare Governance Shake-Up
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already staying ahead of market-moving developments. Click the “Free Alerts” button at StockWire X to get the next big announcement the moment it drops.